Regorafenib in glioblastoma recurrence: A case report
| Autor: | V. Maragna, E. Scoccimarro, Isacco Desideri, M.A. Teriaca, Victoria Lorenzetti, S. Lucidi, Lorenzo Livi, Michele Ganovelli, Beatrice Detti, Silvia Scoccianti, Daniela Greto |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
Oncology Malignant glioma Cancer Research medicine.medical_specialty Pyridines medicine.medical_treatment Brain tumor chemistry.chemical_compound Glioblastoma recurrent Regorafenib Internal medicine Temozolomide medicine Humans In patient RC254-282 Brain Neoplasms business.industry Phenylurea Compounds Neoplasms. Tumors. Oncology. Including cancer and carcinogens Treatment options Chemoradiotherapy Adjuvant Lomustine Middle Aged medicine.disease Magnetic Resonance Imaging nervous system diseases Treatment Outcome chemistry Neoplasm Recurrence Local Glioblastoma business Adjuvant medicine.drug |
| Zdroj: | Cancer Treatment and Research Communications, Vol 26, Iss, Pp 100263-(2021) |
| ISSN: | 2468-2942 |
| Popis: | GBM (glioblastoma multiforme) is the most common and aggressive brain tumor. To date, treatment options for glioblastoma recurrence are lacking. Recently, REGOMA trial showed the superiority of regorafenib to lomustine in patients with first glioblastoma recurrence. We report an excellent response to three months treatment with regorafenib, in a patient who presented a rapid progression after the end of post operative radio-chemotherapy and after only one cycle of adjuvant TMZ (Temozolomide). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect